Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.

The Phase 2 study NCT07269210, officially titled “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia,” aims to test if Eli Lilly’s new drug can safely cut very high blood fat levels. The focus is on lowering triglycerides and other lipids, an area with clear unmet need and sizable market stakes.

The trial tests solbinsiran, also known as LY3561774, given as two shots under the skin. It is compared with a matched placebo shot, with the goal of showing better triglyceride reduction while keeping side effects acceptable for long term use.

This is an interventional Phase 2 trial that randomly assigns adults with severe hypertriglyceridemia to solbinsiran or placebo. Neither patients nor doctors know who gets which treatment, and the main goal is treatment benefit measured by changes in blood fat levels.

The study was first submitted in late November 2025, marking the start of formal trial setup and site activation. The latest update on February 9, 2026, confirms the study remains active and in the recruiting stage, which signals execution progress but no top line data yet.

For investors, this update supports the case that Lilly is building a broader metabolic and cardiovascular portfolio beyond obesity and diabetes. Positive future readouts could support LLY’s premium valuation and pressure rivals in lipid therapies, including players in RNA based drugs and established statin or PCSK9 franchises.

While near term stock impact may be limited without efficacy data, continued pipeline advancement tends to support sentiment in large cap pharma with strong balance sheets like Lilly. The recruiting status and recent update keep this asset on radar for longer term growth drivers in cardiometabolic disease.

This Eli Lilly study of solbinsiran for severe hypertriglyceridemia is ongoing and recently updated, with more detail available on the ClinicalTrials portal.

To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.